Suppression of myoclonus in SCA2 by piracetam

Mov Disord. 2006 Jan;21(1):116-8. doi: 10.1002/mds.20683.

Abstract

We report on a 30-year-old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12-18 gm/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Ataxia / drug therapy*
  • Ataxia / genetics
  • Ataxins
  • Dose-Response Relationship, Drug
  • Gait Ataxia / drug therapy*
  • Gait Ataxia / genetics
  • Humans
  • Infusions, Intravenous
  • Male
  • Myoclonus / drug therapy*
  • Myoclonus / genetics
  • Nerve Tissue Proteins / genetics*
  • Neurologic Examination / drug effects
  • Piracetam / adverse effects
  • Piracetam / therapeutic use*
  • Recurrence
  • Spinocerebellar Ataxias / drug therapy*
  • Spinocerebellar Ataxias / genetics
  • Substance Withdrawal Syndrome / diagnosis
  • Treatment Outcome
  • Trinucleotide Repeats / genetics

Substances

  • Ataxins
  • Nerve Tissue Proteins
  • Piracetam